Trial Profile
Phase 1 study of adoptive cell transfer therapy for advanced cancer patients, using stimulated T cells by CH-296.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Retronectin-induced T-cell therapy (Primary)
- Indications Gastrointestinal cancer; Lung cancer
- Focus Adverse reactions
- 13 May 2014 New trial record